Profile data is unavailable for this security.
About the company
SkinBioTherapeutics plc is a United Kingdom-based life science company, which is focused on skin health. The principal activity of the Company is that of research and development focused on harnessing the microbiome for human health. The Company’s segments include UK, US, and EU. The Company's platform technology, SkinBiotix, applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin. The Company is targeting five specific skin healthcare sectors, such as cosmetics skincare, food supplements for the treatment of skin conditions, medical skin care, infection control in both the home and the hospital environment, and pharmaceuticals for the prescribed treatment of skin conditions. The Company's product, AxisBiotix-Ps, is a food supplement to address the symptoms of mild to moderate psoriasis. The Company is also focused on the application of SkinBiotix technology in the treatment of various classes of skin wounds.
- Revenue in GBP (TTM)161.65k
- Net income in GBP-2.88m
- Incorporated2015
- Employees11.00
- LocationSkinBioTherapeutics PLCThe Core, Newcastle HelixNEWCASTLE UPON TYNE NE4 5TFUnited KingdomGBR
- Phone+44 191 495 7325
- Websitehttps://www.skinbiotherapeutics.com/
More ▼
Mergers & acquisitions
| Acquired company | SBTX:LSE since announced | Transaction value |
|---|---|---|
| Dermatonics Ltd | -37.29% | 3.73m |
Data delayed at least 20 minutes, as of Apr 19 2024 15:26 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shield Therapeutics PLC | 7.21m | -46.89m | 11.54m | 28.00 | -- | 0.3881 | -- | 1.60 | -0.1549 | -0.1549 | 0.0151 | 0.038 | 0.1691 | 1.80 | 0.9805 | -- | -109.95 | -42.77 | -129.39 | -48.12 | 44.76 | 79.44 | -650.12 | -274.35 | 2.64 | -124.94 | 0.1756 | -- | 261.55 | 53.86 | -151.04 | -- | -7.68 | -- |
| Incanthera PLC | 0.00 | -1.48m | 12.67m | 8.00 | -- | -- | -- | -- | -0.0192 | -0.0192 | 0.00 | -0.0086 | 0.00 | -- | -- | 0.00 | -373.20 | -101.74 | -- | -132.88 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -36.11 | -- | -- | -- |
| Abingdon Health PLC | 5.34m | -2.24m | 12.78m | 82.00 | -- | 7.05 | -- | 2.39 | -0.0184 | -0.0184 | 0.0439 | 0.0149 | 0.8978 | 7.67 | 4.74 | 65,170.73 | -37.55 | -51.31 | -58.04 | -79.85 | 57.35 | 33.16 | -41.82 | -139.64 | 1.59 | -- | 0.3572 | -- | 42.68 | -- | 83.77 | -- | -- | -- |
| Synairgen plc | 0.00 | -9.99m | 13.29m | 30.00 | -- | 0.8326 | -- | -- | -0.0496 | -0.0496 | 0.00 | 0.0793 | 0.00 | -- | -- | 0.00 | -41.40 | -54.75 | -48.86 | -60.72 | -- | -- | -- | -83,247.62 | -- | -- | 0.00 | -- | -- | -- | 63.74 | -- | 0.00 | -- |
| Provexis plc | 598.08k | -496.59k | 14.14m | 2.00 | -- | 14.10 | -- | 23.65 | -0.0002 | -0.0002 | 0.0003 | 0.0004 | 0.6717 | 3.04 | 2.95 | 299,040.00 | -55.78 | -48.82 | -41.86 | -33.68 | 46.72 | 86.14 | -83.03 | -97.64 | 1.96 | -- | 0.00 | -- | -8.51 | 10.58 | -71.79 | -- | -- | -- |
| Genincode PLC | 1.72m | -6.73m | 15.48m | 28.00 | -- | 1.76 | -- | 9.02 | -0.0703 | -0.0703 | 0.0179 | 0.0497 | 0.168 | 16.36 | 2.88 | 61,285.71 | -65.92 | -- | -72.37 | -- | 47.55 | -- | -392.31 | -- | 5.85 | -- | 0.0632 | -- | 23.92 | -- | -34.21 | -- | -- | -- |
| Chill Brands Group PLC | 146.62k | -3.64m | 15.95m | 2.00 | -- | -- | -- | 108.77 | -0.0142 | -0.0142 | 0.0006 | -0.0024 | 0.0319 | 0.0992 | 0.3639 | 73,310.00 | -79.21 | -72.55 | -141.46 | -105.35 | 53.05 | -- | -2,485.30 | -1,625.46 | 0.6499 | -8.48 | 1.17 | -- | -86.73 | -50.89 | 23.50 | -- | -35.95 | -- |
| OptiBiotix Health PLC | 689.10k | -13.17m | 17.63m | 3.00 | -- | 1.75 | -- | 25.58 | -0.1489 | -0.1489 | 0.0078 | 0.1029 | 0.0426 | 2.28 | 1.25 | 229,700.00 | -81.35 | 17.83 | -83.43 | 18.66 | 49.31 | 54.87 | -1,911.88 | 190.54 | 3.24 | -0.089 | 0.00 | -- | -79.35 | 19.05 | -58.68 | 6.28 | 30.03 | -- |
| Destiny Pharma PLC | 0.00 | -5.97m | 18.35m | 20.00 | -- | 1.54 | -- | -- | -0.0759 | -0.0759 | 0.00 | 0.1251 | 0.00 | -- | -- | 0.00 | -48.68 | -47.98 | -52.87 | -52.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -21.80 | -- | -45.97 | -- |
| LungLife AI Inc | 36.99k | -4.35m | 18.72m | 19.00 | -- | 1.24 | -- | 506.00 | -0.1708 | -0.1708 | 0.0015 | 0.2497 | 0.0038 | -- | 0.1474 | 1,946.96 | -44.11 | -- | -50.09 | -- | 100.00 | -- | -11,767.39 | -- | -- | -- | 0.0419 | -- | 91.67 | -- | 28.83 | -- | -- | -- |
| Verici DX PLC | 15.28k | -9.02m | 19.42m | 14.00 | -- | 2.54 | -- | 1,271.02 | -0.0529 | -0.0529 | 0.00009 | 0.0316 | 0.0013 | -- | 0.1152 | 1,018.63 | -77.76 | -- | -92.28 | -- | 84.21 | -- | -59,015.79 | -- | -- | -- | 0.0232 | -- | -- | -- | -36.94 | -- | -- | -- |
| Skinbiotherapeutics PLC | 161.65k | -2.88m | 19.54m | 11.00 | -- | 5.08 | -- | 120.86 | -0.0165 | -0.0165 | 0.0009 | 0.0192 | 0.0522 | 0.8871 | 0.4181 | 14,695.45 | -93.07 | -52.07 | -115.26 | -57.33 | 62.90 | -- | -1,784.70 | -4,694.37 | 6.48 | -379.78 | 0.0259 | -- | 76.65 | -- | -1.52 | -- | 18.00 | -- |
| C4X Discovery Holdings PLC | 24.68m | 10.57m | 21.57m | 49.00 | 2.04 | 0.8765 | 1.97 | 0.8738 | 0.0419 | 0.0419 | 0.0979 | 0.0976 | 1.18 | -- | 5.02 | 503,673.50 | 50.37 | -66.17 | 55.00 | -76.79 | 99.94 | 97.43 | 42.81 | -416.04 | -- | -- | 0.0104 | -- | -36.64 | -24.70 | -36.16 | -- | -16.37 | -- |
| Oncimmune Holdings PLC | 1.15m | -6.15m | 21.58m | 56.00 | -- | 32.84 | -- | 18.73 | -0.0859 | 0.0507 | 0.0159 | 0.0089 | 0.1239 | 1.08 | 0.5941 | -- | -66.15 | -- | -131.46 | -- | 68.75 | -- | -533.94 | -- | 3.75 | -1.96 | 0.8897 | -- | -- | -- | -- | -- | -- | -- |
| Hemogenyx Pharmaceuticals PLC | 0.00 | -7.17m | 22.42m | 14.00 | -- | 5.21 | -- | -- | -0.007 | -0.007 | 0.00 | 0.0032 | 0.00 | -- | -- | 0.00 | -95.17 | -73.59 | -107.02 | -86.78 | -- | -- | -- | -- | -- | -71.62 | 0.4735 | -- | -- | -- | 21.96 | -- | 46.18 | -- |
| Sareum Holdings Plc | 0.00 | -4.26m | 27.17m | 5.00 | -- | 45.07 | -- | -- | -0.0614 | -0.0614 | 0.00 | 0.0059 | 0.00 | -- | -- | 0.00 | -160.20 | -71.41 | -195.05 | -81.48 | -- | -- | -- | -19,709.24 | -- | -6.61 | 0.00 | -- | -- | -- | -46.96 | -- | -- | -- |
Data as of Apr 19 2024. Currency figures normalised to SkinBioTherapeutics PLC's reporting currency: UK Pound GBX
18.85%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Yarra Investment Management Ltd.as of 30 Nov 2023 | 13.82m | 7.17% |
| Odd Asset Management Ltd.as of 05 Jan 2023 | 13.17m | 6.83% |
| Unicorn Asset Management Ltd.as of 08 Apr 2024 | 7.89m | 4.10% |
| Evelyn Partners Investment Management LLPas of 31 Dec 2023 | 1.46m | 0.76% |
More ▼
Data from 29 Feb 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
